Filing Details
- Accession Number:
- 0001104659-26-009203
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2026-02-02 16:05:34
- Reporting Period:
- 2026-01-30
- Filing Date:
- 2026-02-02
- Accepted Time:
- 2026-02-02 16:05:34
- SEC Url:
- Form 4 Filing
- 10b5-1 trading plan:
- Unchecked
The filer left the 10b5-1 checkbox unchecked. This is not proof that every trade was unplanned.
A 10b5-1 plan sets trading instructions in advance, so trades follow those instructions instead of a new decision at the time of each trade. The checkbox applies to the filing as a whole and does not identify every covered trade; see the footnotes for details. It reflects the filer's disclosure, not SEC approval of the plan. SEC Form 4 instructions.
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1781983 | Aprea Therapeutics Inc. | APRE | () | 4 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1716213 | P. John Hamill | 3805 Old Easton Road Doylestown PA 18902 | Srvp/Cfo/Prin Fin & Acct Ofcr | No | Yes | No | No |
Transaction Summary
| Purchased: | 5,700 shares | Avg. Price: $0.89 | Total Value: $5,073.00 |
| Number of Shares After Transactions: | 33,433 shares | ||
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2026-01-30 | 5,700 | $0.89 | 33,433 | No | 4 | P | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | P | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Common Warrant | Acquisiton | 2026-01-30 | 5,700 | $0.00 | 5,700 | $0.77 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 5,700 | 2026-01-30 | No | 4 | P | Direct |
Footnotes
- On January 28, 2026, the Issuer entered into a securities purchase agreement with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold to the Reporting Person in a private placement, which closed on January 30, 2026, an aggregate of 5,700 shares of the Issuer's common stock (the "Shares") at a purchase price of $0.89 per Share. The Reporting Person also received accompanying common warrants (the "Common Warrants") to purchase up to an aggregate of 5,700 Shares.
- The Common Warrants are immediately exercisable, provided, that, the Common Warrants cannot be exercised to the extent that, upon giving effect to or immediately prior to such exercise, would cause either (i) the aggregate number of shares of Common Stock beneficially owned by such holder (together with its affiliates) would exceed 4.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise or (ii) the combined voting power of the Issuer's securities beneficially owned by such holder (together with its affiliates) would exceed 9.99% of the combined voting power of all of the Issuer's securities outstanding immediately after giving effect to the exercise.
- The Common Warrants will expire on or prior to 5:00 p.m. (New York City time) on the second year anniversary of the earlier of: (i) the effective date of the registration statement registering the underlying Shares of the Common Warrants and (ii) the date the Shares underlying the Common Warrants are eligible for sale under Rule 144 (assuming cashless exercise of the Common Warrants) without the requirement for the Issuer to be in compliance with the current public information required under Rule 144.
Hedge Fund Resource Center Billionaire Hedge Funds
